针对SARS-CoV-2小分子直接作用抗病毒药物的人类剂量预测的最佳临床前模型
Francesca Toselli1, Sofie Jacobs1, Els Scheers1
1Johnson & Johnson, Turnhoutseweg 30, 2340 Beerse, Belgium.
Antiviral research
|February 11, 2026
概括
预测COVID-19药物的有效人体剂量需要仔细的临床前模型选择. 试验室和K18-hACE2小鼠模型最好地预测了SARS-CoV-2抗病毒药物的人类疗效,例如恩西特里尔维尔和尼尔马特里尔维尔.
科学领域:
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 由于持续的抗病毒限制,COVID-19大流行需要新的治疗方法.
- 准确的人类剂量预测策略对于开发针对SARS-CoV-2的新药至关重要.
研究的目的:
- 评估临床前模型的可翻译性,以预测针对SARS-CoV-2的直接作用抗病毒药物的人类有效暴露.
- 为了与临床数据对比各种体外和体内模型中的恩西特里尔维尔和尼马特里尔维尔的疗效.
主要方法:
- 在A549-hACE2细胞,人类鼻上皮培养物,叙利亚黄金仓鼠和K18-hACE2小鼠中评估了3CLpro抑制剂 (恩西特雷尔维尔,涅马特雷尔维尔/里托纳维尔) 的最小有效度.
- 将临床前数据与现有的临床人类数据进行了COVID-19治疗的比较.
主要成果:
- 实验室模型和K18-hACE2转基因小鼠显示了人类有效药物暴露的最高可预测性.
- 在K18-hACE2小鼠模型中,严重的和轻微的感染需要比叙利亚金模型更低的有效暴露.
- 从体外EC90进行四倍推算,可以为人类有效暴露提供保守的估计.
结论:
- 建议在体外和K18-hACE2小鼠模型中进行SARS-CoV-2抗病毒药物的临床前评估.
- 建议对体外EC90应用4倍因子来估计人类有效暴露,使用K18-hACE2小鼠模型验证.
- 这些发现有助于优化开发和临床试验设计,以获得有效的COVID-19治疗方法.
相关概念视频
Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.9K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.9K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.8K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
Adrenergic Agonists: Direct-Acting Agents
2.9K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.9K
Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.4K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.4K
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
6.8K
All meta-directing substituents are deactivating groups. These substituents withdraw electrons from the aromatic ring, making the ring less reactive toward electrophilic substitution. For example, the nitration of nitrobenzene is 100,000 times slower than that of benzene because of the deactivating effect of the nitro group. The first step in an electrophilic aromatic substitution is the addition of an electrophile to form a resonance-stabilized carbocation. The energy diagrams for...
6.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.2K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.2K


